Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) FCF Margin (2016 - 2025)

Historic FCF Margin for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to 258.61%.

  • CytomX Therapeutics' FCF Margin fell 1965500.0% to 258.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.67%, marking a year-over-year increase of 64500.0%. This contributed to the annual value of 62.66% for FY2024, which is 64700.0% down from last year.
  • As of Q3 2025, CytomX Therapeutics' FCF Margin stood at 258.61%, which was down 1965500.0% from 84.57% recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' FCF Margin registered a high of 39.58% during Q1 2023, and its lowest value of 465.14% during Q1 2022.
  • Its 5-year average for FCF Margin is 169.22%, with a median of 84.57% in 2025.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by -17109300bps in 2021, then soared by 5047200bps in 2023.
  • CytomX Therapeutics' FCF Margin (Quarter) stood at 282.4% in 2021, then soared by 97bps to 7.83% in 2022, then plummeted by -967bps to 83.55% in 2023, then soared by 37bps to 52.47% in 2024, then plummeted by -393bps to 258.61% in 2025.
  • Its FCF Margin stands at 258.61% for Q3 2025, versus 84.57% for Q2 2025 and 41.56% for Q1 2025.